David L Porter

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program
    Chatchada Karanes
    City of Hope National Medical Center, Duarte, California, USA
    Biol Blood Marrow Transplant 14:8-15. 2008
  2. pmc Chimeric Antigen Receptor Therapy for B-cell Malignancies
    David L Porter
    1 Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA
    J Cancer 2:331-2. 2011
  3. doi request reprint CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road
    Saar Gill
    University of Pennsylvania, Abramson Cancer Center, Perelman School of Medicine, Division of Hematology Oncology, Department of Medicine, Philadelphia, PA 19106, USA
    Expert Opin Biol Ther 14:37-49. 2014
  4. doi request reprint Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies
    David L Porter
    Division of Hematology Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Hematology Am Soc Hematol Educ Program 2011:292-8. 2011
  5. pmc NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
    David L Porter
    University of Pennsylvania Medical Center, Philadelphia, 19104, USA
    Biol Blood Marrow Transplant 16:1467-503. 2010
  6. ncbi request reprint T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
    D L Porter
    Department of Medicine, Hematology Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 35:935-42. 2005
  7. ncbi request reprint Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
    D L Porter
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Biol Blood Marrow Transplant 7:230-8. 2001
  8. ncbi request reprint A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
    David L Porter
    Stem Cell Transplant Program, Division of Hematology Oncology, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    Blood 107:1325-31. 2006
  9. ncbi request reprint Donor leukocyte infusions in myeloid malignancies: new strategies
    David L Porter
    University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    Best Pract Res Clin Haematol 19:737-55. 2006
  10. pmc Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    David L Porter
    Abramson Cancer Center, and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 365:725-33. 2011

Research Grants

Detail Information

Publications62

  1. ncbi request reprint Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program
    Chatchada Karanes
    City of Hope National Medical Center, Duarte, California, USA
    Biol Blood Marrow Transplant 14:8-15. 2008
    ..Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years...
  2. pmc Chimeric Antigen Receptor Therapy for B-cell Malignancies
    David L Porter
    1 Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA
    J Cancer 2:331-2. 2011
    ....
  3. doi request reprint CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road
    Saar Gill
    University of Pennsylvania, Abramson Cancer Center, Perelman School of Medicine, Division of Hematology Oncology, Department of Medicine, Philadelphia, PA 19106, USA
    Expert Opin Biol Ther 14:37-49. 2014
    ..T cells that are genetically engineered to express chimeric antigen receptors (CARs) recognizing the B-cell-associated molecule CD19 have emerged as a potentially potent and exciting therapeutic modality in recent years...
  4. doi request reprint Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies
    David L Porter
    Division of Hematology Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Hematology Am Soc Hematol Educ Program 2011:292-8. 2011
    ....
  5. pmc NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
    David L Porter
    University of Pennsylvania Medical Center, Philadelphia, 19104, USA
    Biol Blood Marrow Transplant 16:1467-503. 2010
    ..In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT...
  6. ncbi request reprint T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
    D L Porter
    Department of Medicine, Hematology Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 35:935-42. 2005
    ..These data all support the premise that adoptive therapy can accelerate reconstitution of cellular immunity with enhanced antitumor effects following SCT...
  7. ncbi request reprint Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
    D L Porter
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Biol Blood Marrow Transplant 7:230-8. 2001
    ..Most patients developed donor chimerism with minimal conditioning. Alternative prophylactic regimens that control GVHD while maintaining GVT are needed to improve outcomes in these heavily pretreated patients...
  8. ncbi request reprint A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
    David L Porter
    Stem Cell Transplant Program, Division of Hematology Oncology, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    Blood 107:1325-31. 2006
    ..Adoptive transfer of costimulated activated allogeneic T cells is feasible, does not result in excessive GVHD, and may contribute to durable remissions in diseases where conventional DLI has been disappointing...
  9. ncbi request reprint Donor leukocyte infusions in myeloid malignancies: new strategies
    David L Porter
    University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    Best Pract Res Clin Haematol 19:737-55. 2006
    ..Although many issues remain unsettled, the potential to harness the graft-versus-leukemia activity of allogeneic donor cells provides a powerful new paradigm for the immunotherapy of cancer...
  10. pmc Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    David L Porter
    Abramson Cancer Center, and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 365:725-33. 2011
    ..Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect...
  11. doi request reprint Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation
    Anita J Kumar
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Biol Blood Marrow Transplant 19:1094-101. 2013
    ..Relapse remains the major cause of treatment failure after RIC HSCT even with rapid withdrawal of immune suppression and the use of prophylactic aDLI, and better strategies to prevent relapse are needed...
  12. doi request reprint Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
    Daniel J Landsburg
    Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Am J Hematol 88:657-60. 2013
    ..Our analysis reveals the benefit of prolonged therapy in the treatment of older adults with ALL as well as the high incidence of treatment-related toxicity experienced by these patients...
  13. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
    ..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy...
  14. ncbi request reprint Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
    Ginna G Laport
    Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Blood 102:2004-13. 2003
    ....
  15. ncbi request reprint Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
    Dan T Vogl
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 82:1071-5. 2007
    ..Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit...
  16. pmc Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
    Ran Reshef
    Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    N Engl J Med 367:135-45. 2012
    ..The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans...
  17. pmc T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    Michael Kalos
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Sci Transl Med 3:95ra73. 2011
    ....
  18. doi request reprint Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies
    Steven C Goldstein
    Division of Hematology Oncology BMT, Abramson Cancer Center, University of Pennsylvania Medical Center, 2 Perelman, 3400 Civic Center Blvd, Philadelphia, PA, USA
    Expert Rev Hematol 3:301-14. 2010
    ....
  19. ncbi request reprint Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Clin Transplant 19:644-52. 2005
    ..68 wk, p = 0.003). Persistence of MG after complete response of the PTLD did not predict relapse. There is a high incidence of MG and gammaglobulin abnormalities in patients with PTLD...
  20. ncbi request reprint Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report
    Thomas P Sollecito
    Division of Oral Medicine, School of Dental Medicine, 4001 Spruce Street, University of Pennsylvania, Philadelphia, PA 19104, USA
    Spec Care Dentist 23:108-10. 2003
    ..This case history raises the possibility that leukemic sanctuary sites may exist, and that monoclonal antibody therapy may have sub-optimal activity in non-medullary sites of disease...
  21. ncbi request reprint Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
    Dan T Vogl
    Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA
    Leuk Lymphoma 46:1313-20. 2005
    ..Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion...
  22. ncbi request reprint A predictive model for the detection of tumor lysis syndrome during AML induction therapy
    Anthony R Mato
    Hematologic Malignancies Program, Division of Hematology and Oncology, Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Leuk Lymphoma 47:877-83. 2006
    ..This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population...
  23. pmc Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02214, USA
    Biol Blood Marrow Transplant 18:1446-54. 2012
    ..Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS...
  24. pmc Graft-versus-host disease after donor leukocyte infusions: presentation and management
    Noelle V Frey
    Division of Hematology Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, 16 Penn Tower, 3400 ISpruce St, Philadelphia PA 19106, USA
    Best Pract Res Clin Haematol 21:205-22. 2008
    ....
  25. pmc Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality
    Noelle V Frey
    Division of Hematology Oncology and Abramson Cancer Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Hematol 83:846-9. 2008
    ..The case illustrates the importance of identifying donor-derived constitutional abnormalities to avoid the assumption that these cytogenetic abnormalities after HSCT are representative of malignant disease...
  26. ncbi request reprint Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation
    Alison W Loren
    Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biol Blood Marrow Transplant 12:758-69. 2006
    ..Until the effects of pregnancy on the maternal immune system are better understood, it is appropriate whenever possible to avoid parous female donors and to choose male donors for male recipients in HLA-identical related donor SCT...
  27. ncbi request reprint Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation
    Alison W Loren
    Stem Cell Transplant Program and Hematology Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, 19104, USA
    Curr Opin Oncol 18:107-14. 2006
    ..But the role for unrelated-donor leukocyte infusion is not well established...
  28. ncbi request reprint Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation
    A W Loren
    Bone Marrow and Stem Cell Transplant Programs, University of Pennsylvania Cancer Center, Philadelphia, PA, USA
    Bone Marrow Transplant 35:921-6. 2005
    ..05). The combination of Cs/MMF is inadequate GVHD prophylaxis for UD-NST. The use of Cs, MTX, and alemtuzumab eliminated severe acute GVHD; its impact on response merits further study...
  29. pmc Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 368:1509-18. 2013
    ..The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL...
  30. ncbi request reprint Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Donald E Tsai
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA
    Clin Lymphoma 4:56-9. 2003
    ..This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma...
  31. ncbi request reprint Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation
    Jose Leis
    Bone Marrow and Stem Cell Transplant Program, Oregon Health Sciences University, Portland, USA
    Leuk Lymphoma 43:9-17. 2002
    ....
  32. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy
    R J Buckanovich
    Bone Marrow and Stem Cell Transplant Program, Division of Hematology Oncology and Department of Medicine, University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia 19104, USA
    Ann Hematol 81:410-3. 2002
    ..However, it demonstrates the potential for severe complications related to immunosuppression, especially in heavily pretreated patients. The toxicity after NMASCT should not be understated and will need to be explored further...
  33. ncbi request reprint Donor leukocyte infusions in acute myelogenous leukemia
    D L Porter
    Bone Marrow and Stem Cell Transplant Program, Hematology Oncology Division, 16 Penn Tower, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Leukemia 17:1035-7. 2003
  34. doi request reprint Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect
    Saar Gill
    Abramson Cancer Center, Department of Medicine, Perelman School of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Annu Rev Med 64:101-17. 2013
    ..Reduced intensity has allowed a potentially curative therapy for hematologic malignancies to be offered to an expanded patient population. Ongoing research seeks to enhance the safety and power of this form of allogeneic immunotherapy...
  35. pmc Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation
    Gregory L Beatty
    Abramson Family Cancer Research Institute, Abramson Cancer Center, Department of Pathology and Laboratory Medicine, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Cancer Res 15:4944-53. 2009
    ..CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood...
  36. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
    ..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)...
  37. ncbi request reprint Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation
    Elizabeth O Hexner
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biol Blood Marrow Transplant 13:1135-44. 2007
    ..CD3/CD28 costimulation of UCB T cells represents a potential strategy for enhancing the engraftment of UCB...
  38. doi request reprint Cutaneous Hodgkin's disease
    Camille E Introcaso
    Department of Dermatology, The University of Pennsylvania, Philadelphia, USA
    J Am Acad Dermatol 58:295-8. 2008
    ..A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease...
  39. ncbi request reprint Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation
    John Gerecitano
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    J Hematother Stem Cell Res 12:215-23. 2003
    ....
  40. pmc Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)
    R Reshef
    Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:336-47. 2011
    ..Patients with none or one of these factors had a 3-year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low-risk PTLD and suggest factors that predict response and survival...
  41. ncbi request reprint Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients
    D E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Transplantation 71:1076-88. 2001
    ..With the increased use of organ transplantation and intensive immunosuppression, this disease is becoming more common. We explore reduction in immunosuppression as an initial therapy for PTLD...
  42. ncbi request reprint Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
    D L Porter
    Division of Hematology Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Blood 95:1214-21. 2000
    ..UDLI is an acceptable alternative to other treatment options for relapse after unrelated donor BMT. (Blood. 2000;95:1214-1221)..
  43. ncbi request reprint Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination
    E A Stadtmauer
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Med Oncol 16:279-88. 1999
    ....
  44. ncbi request reprint Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies
    D L Porter
    Division of Hematology Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 17:1234. 1999
    ....
  45. ncbi request reprint Novel approaches to allogeneic stem cell therapy
    V Bhatia
    Bone Marrow and Stem Cell Transplant Program, Hematology-Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Expert Opin Biol Ther 1:3-15. 2001
    ..In addition, the durability of response is unknown. Nevertheless, the use of non-myeloablative conditioning and ACT may provide a new paradigm for allogeneic cell transplantation and the immunotherapy of cancer...
  46. ncbi request reprint Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma
    C Andreadis
    Bone Marrow and Stem Cell Transplantation Program and Lymphoma Program, The Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, 19104, USA
    Bone Marrow Transplant 36:955-61. 2005
    ..ASCT is thus a safe therapeutic approach in FL, resulting in long-term EFS and OS for some patients, even with transformed disease...
  47. ncbi request reprint The graft-versus-leukemia effects of allogeneic cell therapy
    D L Porter
    Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Annu Rev Med 50:369-86. 1999
    ....
  48. ncbi request reprint Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer
    M A Morgan
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Gynecol Oncol 67:272-6. 1997
    ..The objective was to determine the toxicity and surgically documented response rate of sequential high-dose chemotherapy with peripheral stem cell support in patients with persistent or recurrent cisplatin-sensitive ovarian cancer...
  49. ncbi request reprint Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
    J Svoboda
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 38:211-6. 2006
    ..A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT...
  50. ncbi request reprint Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation
    A W Loren
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 41:483-93. 2008
    ..This review discusses the rationale, biology, complications and future applications of DLI in acute leukemia patients after allogeneic SCT...
  51. ncbi request reprint 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning
    D L Porter
    Bone Marrow and Stem Cell Transplant Program, Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Bone Marrow Transplant 31:739-46. 2003
    ..Nonmyeloablative conditioning and allogeneic SCT may induce a direct GVHL reaction with less conditioning regimen-related toxicity and ultimately may have the potential to improve cure rates and survival for advanced HL patients...
  52. pmc Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
    R L Olin
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 43:417-22. 2009
    ..We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma...
  53. doi request reprint Chimeric antigen receptor therapy for cancer
    David M Barrett
    Abramson Cancer Center and the Departments of Medicine, Pediatrics, and Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 email
    Annu Rev Med 65:333-47. 2014
    ..The potential to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be made opens up an entirely new arena for targeted therapy of cancer. ..
  54. ncbi request reprint Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications?
    Lauren J Kaufman
    Department of Radiology, Division of Interventional Radiology and Medicine, University of Pennsylvania Medical Center, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Vasc Interv Radiol 15:57-61. 2004
    ....
  55. ncbi request reprint Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin level
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 83:253. 2008
  56. pmc Circulating osteogenic precursor cells in heterotopic bone formation
    Robin K Suda
    Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104 6160, USA
    Stem Cells 27:2209-19. 2009
    ..Thus, bone formation is not limited to cells of the mesenchymal lineage, and circulating cells of hematopoietic origin can also serve as osteogenic precursors at remote sites of tissue inflammation...
  57. ncbi request reprint Umbilical cord blood transplantation: where do we stand?
    Raymond C Wadlow
    Bone Marrow and Stem Cell Transplant Program, Hematology Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Biol Blood Marrow Transplant 8:637-47. 2002
    ..This overview examines the advantages and disadvantages of UCB as a donor source and reviews data from preclinical and clinical studies. Ethical issues regarding UCB transplantation are also addressed...
  58. ncbi request reprint Post-transplant lymphoproliferative disorder: a review
    A W Loren
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 31:145-55. 2003
    ....
  59. ncbi request reprint Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Am J Transplant 2:946-54. 2002
    ..We conclude that peripheral blood EBV PCR may have a role in the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients...
  60. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease
    A D Cohen
    Hematologic Malignancies Program and the Bone Marrow and Stem Cell Transplantation Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 30:23-8. 2002
    ..The other seven patients did not meet diagnostic criteria for VOD. We conclude that GO can be safe and effective in patients who relapse following HSCT, but that caution is warranted in patients with multiple risk factors for VOD...
  61. ncbi request reprint Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation
    John E Levine
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 20:405-12. 2002
    ..A chemotherapy strategy was used to debulk disease before administration of granulocyte colony-stimulating factor (G-CSF)-primed DLIs...
  62. ncbi request reprint Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
    Aaron P Rapoport
    University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
    Nat Med 11:1230-7. 2005
    ..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses...

Research Grants2